Pair Name	Phenethyl isothiocyanate, Dasatinib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Inhibition-->Angiogenesis
Gene Regulation	Up-regulation	Expression	CDH1	hsa999
	Down-regulation	Expression	CDH2	hsa1000
	Down-regulation	Phosphorylation	PTK2	hsa5747
	Down-regulation	Phosphorylation	STAT3	hsa6774
	Down-regulation	Expression	VEGFA	hsa7422
In Vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
	Hepa 1-6	Hepatocellular carcinoma of the mouse	Mus musculus (Mouse)	CVCL_0327
Result	The inhibition of FAK/STAT3 signalling led to increased E-cadherin expression and reduced VEGF secretion, reducing HCC metastatic potential. Therefore, a combination of PEITC and dasatinib could be a potential therapeutic strategy for the treatment of HCC.

Pair Name	Phenethyl isothiocyanate, Dasatinib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation	Up-regulation	Phosphorylation	AIFM1	hsa9131
	Down-regulation	Expression	CCNB1	hsa891
	Down-regulation	Expression	CDK1	hsa983
	Down-regulation	Expression	KEAP1	hsa9817
	Up-regulation	Cleavage	PGAM5	hsa192111
In Vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
	Hepa 1-6	Hepatocellular carcinoma of the mouse	Mus musculus (Mouse)	CVCL_0327
In Vivo Model	Hepa 1-6 cells (5×10⁶ cells in 100 µL MEM) were injected subcutaneously in the right flank of 40 9–10-week-old female C57BL6 mice.
Result	PEITC showed to enhance dasatinib action in treating HCC with increased production of ROS that induced cell cycle arrest followed by mitotic catastrophe, and to induce oxeiptosis. These results highlight the role that ITCs may have in cancer therapy as a complement of clinically approved chemotherapeutic drugs